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Treatment outcomesThe association between varying durations of previous vancomycin therapy and subsequent daptomycin success
rates was evaluated in a subset of patients with methicillin-resistant Staphylococcus aureus bacteremia from the
Cubicin® Outcomes Registry and Experience 2005–2009 (n = 159). Previous vancomycin exposure did not ad-
versely affect daptomycin outcomes; success rates were 81% in patients treated with ﬁrst-line daptomycin and
89%, 83%, and 88%, respectively, in patients with 1–3 days, 4–6 days, and ≥7 days of previous vancomycin expo-
sure (P= 0.5).
© 2015 Merck Sharp & Dohme Corp., a subsidiary of Merck and Co., Inc. and The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There is a concern among some clinicians that previous exposure to
vancomycin might compromise the activity of daptomycin for serious
methicillin-resistant Staphylococcus aureus (MRSA) infection.
Vancomycin-induced changes in cell membrane thickness among
vancomycin-heteroresistant S. aureus strains might lead to impaired
daptomycin diffusion through the cell wall (Cunha and Pherez, 2009;
Moise et al., 2009; Nannini et al., 2010; Sakoulas et al., 2006; van Hal
et al., 2011). This notion is supported by a recently published in vitro
model that showed reduced daptomycin activity after exposure to van-
comycin and in vitro data that suggested a shift toward higher dapto-
mycin MICs in patients previously exposed to vancomycin (Bhalodi
et al., 2014; Moise et al., 2008; Patel et al., 2006). Despite this concern,
limited clinical data support this in vitro observation (Sakoulas et al.,
2009). Furthermore, data are limited regarding the clinical implications
of MRSA infections with high vancomycin MIC values and prior vanco-
mycin exposure on subsequent outcomes of patients who received dap-
tomycin (Boucher and Sakoulas, 2007; Kullar et al., 2013; Moore et al.,
2012; Murray et al., 2013; Rehm et al., 2008). Given this gap in the liter-
ature, the aim of this study was to assess the impact of the duration of
prior vancomycin exposure, stratiﬁed by the vancomycin MIC and0th Interscience Conference on
5, 2010, Boston, MA.
1-781-240-2457.
aw).
ofMerck and Co., Inc. and The Authorsdaptomycin dose received, on outcomes of patients with MRSA blood-
stream infections treated with daptomycin.
2. Materials and methods
To accomplish the study objective, data were obtained from the
Cubicin® Outcomes Registry and Experience (CORE®), a multicenter,
retrospective, observational chart review that collected the
postmarketing experience with daptomycin in the United States
(Rolston et al., 2007). At each site, approximately 25 patients, treated
with 1 or more doses of daptomycin and not part of a clinical trial,
were selected retrospectively in a consecutive fashion each year to re-
duce the potential for bias. In this post hoc analysis, we considered
COREpatients from January 2005 toDecember 2009 if theywere report-
ed to have documented MRSA bacteremia and had an evaluable treat-
ment response (clinically evaluable) after daptomycin therapy. The
clinically evaluable population excluded those with infection response
classiﬁed as nonevaluable; the infection response was classiﬁed as
nonevaluable if the investigator could not determine response at the
end of therapy because of insufﬁcient information in the record.
All baseline data elements available in the CORE registry were con-
sidered in this analysis. Previous vancomycin usewas deﬁned as vanco-
mycin used before daptomycin therapy for the same infection episode.
For the purposes of analyses, previous vancomycin exposure was cate-
gorized as follows: 0 days (daptomycin ﬁrst line), 1–3 days, 4–6 days,
and ≥7 days. Vancomycin and daptomycin MIC values were as reported
at each institution using their preferred MIC testing methodology (MIC
testing methods were not collected). Investigator-assessed clinical. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
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and was classiﬁed as follows: cure—clinical signs and symptoms are re-
solved and no additional antibiotic drug therapy is necessary, or the in-
fection cleared with a negative culture reported at the end of therapy;
improved—partial resolution of clinical signs and symptoms and addi-
tional antibiotic drug therapy necessary at the end of therapy; and
failure—inadequate response to therapy; resistant, worsening, or new/
recurrent signs and symptoms; a need for a change in antibiotic drug
therapy; or a positive culture result reported at the end of therapy.Table 1
Patient demographics, baseline infection characteristics, and daptomycin dosing details (evalu
Characteristic Daptomycin ﬁrst line (n = 47
Sex, n (%)
Male 29 (62)
Weight (kg), mean (SD) 82 (24)
Age group (y), n (%)
≥66 18 (38)
Location 2 days before daptomycin administration, n (%)
Communitya 24 (51)
Hospital 18 (38)
Nursing home/extended care 5 (11)
Daptomycin administration setting, n (%)
Any inpatient therapy 46 (98)
Any outpatient therapy 12 (26)
Concurrent diseases (≥14%), n (%)b
Hypertension 25 (53)
Diabetes mellitus 15 (32)
Chronic renal failure 10 (21)
Anemia/hematologic disease 6 (13)
Cancerc 6 (13)
Congestive heart failure 4 (9)
ICU stay, n (%)d 17 (36)
CrCl b30 mL/min at start of daptomycin, n (%)e 18 (38)
Dialysis at start of daptomycin, n (%) 10 (21)
Surgical intervention, n (%) 11 (55)f
Concomitant infection types, n (%)
Catheter related 14 (30)
Endocarditis 11 (23)
Osteomyelitis 6 (13)
Pathogen, n (%)g
MRSA only 38 (81)
MRSA with copathogens 9 (19)
Vancomycin MIC (mg/L)
b2 17 (36)
≥2 10 (21)
Otherh 20 (43)
Daptomycin MIC (mg/L)
≤1 9
N1 2
Unknown 36
Initial daptomycin dose, median (min, max) 6 (4, 10)
Dose ≥6 mg/kgi, n (%) 34 (72)
Dose b6 mg/kg, n (%) 13 (28)
Dose ≥8 mg/kg, n (%) 3 (6)
Dose b8 mg/kg, n (%) 44 (94)
Administration, n (%)
Once daily 33 (70)j
Once every 2 days 11 (23)
3 times/wk 2 (4)
Median treatment duration (min, max) 12 (1, 67)
CrCL = creatinine clearance; ICU = intensive care unit.
a P b 0.001 comparing community setting for all groups, chi-square.
b Patients might have more than 1 concurrent disease.
c Includes solid organ and hematologic cancer.
d Intensive care unit stay at any time while receiving daptomycin.
e Creatinine clearance calculated using Cockcroft–Gault equation.
f Surgical intervention data were not collected for 27 daptomycin ﬁrst-line patients; percent
g All patients had MRSA bacteremia; up to 4 pathogens reported from any culture site.
h Included 27 patients with a reported vancomycin MIC of ≤2 mg/L, which could not be incl
i There was a trend in dosing ≥6 mg/kg for all groups (P = 0.06).
j One patient received a single dose with unknown frequency.Vancomycin therapy failure prior to daptomycin was assessed with
the same deﬁnition (Rolston et al., 2007). Treatment successwas deﬁned
as the sum of cured and improved status.
Categorical variables were compared using chi-square analysis or
the Fisher exact test, as appropriate. Continuous variables were com-
pared using the Kruskal–Wallis analysis of variance. The analyses were
also stratiﬁed within infection types (endocarditis and catheter-
related bacteremia), concomitant antibiotic use including β-lactams,
vancomycin failure, daptomycin dose, vancomycin MIC, andable population).
) Previous vancomycin use Total (n = 159)
1–3 days (n = 37) 4–6 days (n = 23) ≥7 days (n = 52)
20 (54) 10 (44) 32 (62) 91 (57)
84 (30) 72 (16) 84 (32) 81 (27)
12 (32) 8 (35) 17 (33) 55 (35)
9 (24) 2 (9) 10 (19) 45 (28)
26 (70) 19 (83) 38 (73) 101 (64)
2 (5) 2 (9) 4 (8) 13 (8)
36 (97) 23 (100) 50 (96) 155 (97)
16 (43) 8 (35) 24 (46) 60 (38)
14 (38) 16 (70) 27 (52) 82 (52)
13 (35) 9 (39) 23 (44) 60 (38)
10 (27) 10 (44) 13 (25) 43 (27)
7 (19) 7 (30) 7 (13) 27 (17)
11 (30) 3 (13) 7 (13) 27 (17)
6 (16) 5 (22) 7 (13) 22 (14)
9 (24) 7 (30) 17 (33) 50 (31)
9 (24) 9 (39) 14 (27) 50 (31)
9 (24) 7 (30) 11 (21) 37 (23)
19 (51) 15 (65) 31 (60) 76 (58)f
13 (35) 11 (48) 17 (33) 55 (35)
4 (11) 3 (13) 17 (33) 35 (22)
2 (5) 3 (13) 8 (15) 19 (12)
26 (70) 20 (87) 45 (87) 129 (81)
11 (30) 3 (13) 7 (13) 30 (19)
14 (38) 7 (30) 21 (40) 59 (37)
10 (27) 8 (35) 9 (17) 37 (23)
13 (35) 8 (35) 22 (42) 63 (40)
15 10 12 46
0 0 1 3
22 13 39 110
6 (4, 9.6) 6 (4, 10) 6 (4,8) 6 (4, 10)
35 (95) 18 (78) 44 (85) 131 (82)
2 (5) 5 (22) 8 (15) 28 (18)
3 (8) 2 (9) 4 (8) 12 (8)
34 (92) 21 (91) 48 (92) 147 (92)
28 (76) 15 (65) 36 (69) 112 (70)j
8 (22) 7 (30) 11 (21) 37 (23)
1 (3) 1 (4) 5 (10) 9 (6)
15 (2, 119) 14 (3, 116) 18 (2, 65) 15 (1, 119)
ages are calculated accordingly.
uded in the assessed categories, and 36 with unreported values.
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Fig. 1.Clinical outcomes: percentage of patientswith success (cured and improved) at end
of daptomycin therapy.
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Patients with unknown or values outside the stratiﬁcationwere exclud-
ed from the analyses. Statistical signiﬁcance was deﬁned as P b 0.05. All
statistics were performed using JMP, version 9.0, or SAS® version 9.1.3
(SAS Institute, Cary, NC, USA).
3. Results
In CORE 2005–2009, 214 patients hadMRSA bacteremia, and vanco-
mycin duration data were available; 159 patients (74%) were clinically
evaluable. Table 1 summarizes patient demographics, baseline infection
characteristics, and daptomycin dosing details for the evaluable popula-
tion. In evaluable patients, vancomycin was used immediately before
daptomycin for 0, 1–3, 4–6, or ≥7 days in 47 (30%), 37 (23%), 23
(14%), and 52 (33%) patients, respectively. Median (range) duration of
vancomycin therapy in the ≥7 day group was 10 (7–30) days. The pa-
tient characteristics across categories were similar with respect to
those that have been associated with failure in CORE (Sakoulas et al.,
2009). Most patients received a daptomycin dose between 6 and
7 mg/kg, and this did not differ signiﬁcantly between the prior vanco-
mycin duration groups. Patients in the daptomycin ﬁrst-line group did
not receive previous antibiotic therapy for their current infection.
Among patients in the previous vancomycin cohorts, previous vanco-
mycin therapywas ineffective in 52 of 112 patients (46%). Themost fre-
quent reason for switching to daptomycin was unsuccessful
vancomycin therapy. There was a trend for more vancomycin failures
reported as the reason for switch with longer vancomycin durations:
12/36 (33%) in the 1- to 3-day cohort, 10/23 patients (43%) in the 4-
to 6-day cohort, and in 30/52 patients (58%) in the ≥7-day cohort;
P=0.06. The distribution of other reasons for switching from vancomy-
cin to daptomycin did not reveal any patterns, with vancomycin resis-
tance (n = 11), allergy or toxicity (n = 8), and clinically unchanged
(n= 7) most frequently identiﬁed after vancomycin failure. Antibiotics
were used in combination with daptomycin in 63% of patients (66% in
daptomycin ﬁrst-line and 62% in all vancomycin cohorts). Overall, 34%
received a β-lactam with daptomycin and was similar across all vanco-
mycin duration categories. Vancomycin MICs were available for 77% of
patients. Among patients with known vancomycinMIC, the distribution
of vancomycin MIC ≥2 mg/L did not differ across the vancomycin dura-
tion categories: 10/39 (26%) in the daptomycin ﬁrst-line cohort, 10/32
(31%) in the 1- to 3-day cohort, 8/19 (42%) in the 4- to 6-day cohort,
and 9/33 (27%) in the ≥7-day cohort; P = 0.6. Daptomycin MICs were
only available for 49 patients (31%) but were evenly distributed across
the vancomycin duration categories. Three patients had MRSA isolates
with daptomycin MICs ≥2 mg/L.
Overall, treatment success was reported in 86% (136 of 159) of pa-
tients at the end of daptomycin therapy. According to previous vanco-
mycin exposure, treatment success (cured/improved) was reported in
81% (34.0%/46.8%) for the daptomycin ﬁrst-line cohort, in 89% (54.1%/
35.1%) for the 1- to 3-day cohort, in 83% (43.5%/39.1%) for the 4- to 6-
day cohort, and in 88% (53.8%/34.6%) for the ≥7-day cohort (Fig. 1).
Treatment success rateswere not signiﬁcantly different between groups
(P = 0.5). In 100 of 159 evaluable patients (63%), time to clinical re-
sponse was reported. Median (range) time to clinical response was 4
(1–113) days overall and was similar between the daptomycin ﬁrst-
line group (3 days) and the previous vancomycin cohorts, 1- to 3-day
(4 days), 4- to 6-day (4 days), and ≥7-day cohorts (3 days).
A number of subsets of evaluable patients were further analyzed for
level of treatment success after daptomycin therapy. Among patients
with endocarditis, treatment success was numerically lower in the dap-
tomycin ﬁrst-line group (6 of 11 patients [55%]) versus all previous van-
comycin cohorts (21 of 24 patients [88%]); however, the difference was
not statistically signiﬁcant (P = 0.09). Success rates were similar be-
tween groups when stratiﬁed by catheter-related (87%) versus non–
catheter-related bacteremia (85%), P = 0.6, and by infection with
MRSA only (85%) versus MRSA plus other pathogens (87%), P = 0.6.Treatment success among patients in whom previous vancomycin ther-
apywas ineffectivewas seen in 10 of 12 patients (83%) in the1- to 3-day
cohort, 8 of 10 patients (80%) in the 4- to 6-day cohort, and 25 of 30 pa-
tients (83%) in the ≥7-day cohort; P = 0.7. The use of concomitant
β-lactam antibiotics in combination with daptomycin did not have an
impact on response to daptomycin either in the whole population
(45/54, 83% with β-lactam and 91/105, 87% without β-lactam) or
when stratiﬁed by prior vancomycin duration (data not shown); P =
0.7. We were also unable to detect a difference between treatment suc-
cess and daptomycin dose received by prior vancomycin duration; P=
0.5 (Table 2). Overall, daptomycin success rates by vancomycin MIC
were 86% (51/59, b2mg/L) and 84% (31/37, ≥2mg/L); P=0.7. The van-
comycin MIC was not found to modify the relationship between prior
vancomycin duration and success; P=0.6 (Table 2). In the limited sub-
set with daptomycin MICs (n= 49), the overall success rate for the pa-
tients with daptomycin MICs ≤1 mg/L was 91% (42/46) Success rates in
patients with daptomycin MIC ≤0.5 mg/L or 1 mg/L were similar. Of
note, the 3 patients with nonsusceptible daptomycin MICs N1 mg/L
were failures. When daptomycin success rates by vancomycin duration
were stratiﬁed by known daptomycin MIC, no trends were apparent.
4. Discussion
Overall, previous vancomycin exposure was not found to adversely
affect daptomycin success among patients with MRSA bloodstream in-
fections from the CORE registry. This ﬁnding held when subgrouping
data by the daptomycin dose received, vancomycin failure, vancomycin
MIC value for the index MRSA isolate, presence of IE, and concomitant
receipt of β-lactams. The ﬁndings from this study align with several re-
cent studies (Kullar et al., 2013; Moore et al., 2012; Murray et al., 2013;
Rehmet al., 2008). In the S. aureusbacteremia and infective endocarditis
registration study, previous vancomycin exposure did not adversely af-
fect the outcomes of patients withMRSA bloodstream infections treated
with daptomycin (Rehm et al., 2008). A recent observational study by
Moore et al. (2012) also found that previous vancomycin exposure did
not compromise the clinical effectiveness of daptomycin among pa-
tients with MRSA bloodstream infections with high vancomycin MIC
values. Interestingly, mortality rates in that study were lower for
daptomycin-treated patients than for vancomycin-treated patients de-
spite 91% of daptomycin-treated patients having received previous van-
comycin. This ﬁnding is consistent with 2 recent retrospective cohort
studies that compared the outcomes of patients with MRSA bacteremia
with vancomycin MICs N1 mg/L treated with either daptomycin or van-
comycin (Kullar et al., 2013; Murray et al., 2013). Despite all daptomy-
cin patients having received previous vancomycin for a median of
1.7 days (all b72 hours), Murray et al. (2013) found that the failure
Table 2
Daptomycin success stratiﬁed by daptomycin dose and vancomycin MIC.
Characteristic, n (%) Daptomycin ﬁrst line (n = 47) Previous vancomycin use Total (n = 159)
1–3 days (n = 37) 4–6 days (n = 23) ≥7 days (n = 52)
Initial daptomycin dose
≥6 mg/kg, n = 131 27 (79) 31 (89) 15 (83) 38 (86) 111 (85)
b6 mg/kg, n = 28 11 (85) 2 (100) 4 (80) 8 (100) 25 (89)
Initial daptomycin dose
≥8 mg/kg, n = 12 1 (33) 3 (100) 2 (100) 3 (75) 9 (75)
b8 mg/kg, n = 147 37 (84) 30 (88) 17 (81) 43 (90) 127 (86)
Vancomycin MIC (mg/L)
b2, n = 59 17 (100) 10 (71) 6 (86) 18 (86) 51 (86)
≥2, n = 37 7 (70) 10 (100) 6 (75) 8 (89) 31 (84)
Other, n = 63a 14 (70) 13 (100) 7 (88) 20 (91) 54 (86)
a Included 27 patients with a reported vancomycin MIC of ≤2 mg/L, which could not be included in the assessed categories, and 36 with unreported values.
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(3.5% versus 12.9%; P=0.047) favored daptomycin over vancomycin. In
their pre- and post-clinical pathway implementation outcome study,
Kullar et al. (2013) similarly noted higher success rates in the daptomy-
cin group than in the vancomycin group. Again, in this study, almost all
patients in the daptomycin group received at least 48 hours of vanco-
mycin (Kullar et al., 2013).
Our study has several limitations. This was a retrospective study and
is subject to all the limitations associated with this design. Although pa-
tient characteristics were similar across the categories, in almost 50% of
patients, the current therapy before daptomycin was unsuccessful,
which may have inﬂuenced success rates. Total vancomycin exposure
might be underestimated because only courses immediately before
daptomycin were reported. Furthermore, CORE outcomes were limited
to end-of-therapy determinations, preventing the assessment of long-
term success. Vancomycin MICs were not reported for 23% of patients,
and data on the attainment of target vancomycin levels were not col-
lected. The lack of daptomycinMICdata in themajority of patients limits
our evaluation of the factor. In addition, most patients in our study re-
ceived a daptomycin dose of 6–7 mg/kg. This differs from the IDSA
MRSA guidelines, which state that some experts recommend daptomy-
cin 8–10 mg/kg for adult patients with complicated MRSA bacteremia.
For adult patients with persistent bacteremia or vancomycin failure,
the IDSA MRSA guidelines also recommend high-dose daptomycin
(10 mg/kg/d), if the isolate is susceptible, in combination with another
agent (Liu et al., 2011). We had a limited number of patients in the
≥8 mg/kg cohort and, therefore, were unable to detect any impact of a
higher dose; the guideline recommendations deserve further evalua-
tion. Gram-negative pathogens and surgical interventions might have
been underreported. In these types of analyses, it is customary to per-
formmultivariate analyses to adjust for potential confounders. Howev-
er, we were limited by the sample size and number of nonsuccesses
(n = 23), which were evenly distributed across our a priori deﬁned
prior vancomycin exposure categorical variable, within the study popu-
lation to ﬁt a meaningful multivariate model to the data. Since nearly
70% (n= 107/159) of the study population received 6 mg/kg of dapto-
mycin, we also did not think that it was prudent to consider a continu-
ous expression of daptomycin dosing in multivariate analyses given the
narrow variability of dosing in our limited study sample. Finally, this
was a hypothesis-generating study. There were no formal sample size
and power calculations. As such, the possibility of type 2 error ﬁndings
exists, and further adequately powered, hypothesis-testing prospective
studies are needed to validate the ﬁndings.Conclusion
In conclusion, the current study found that daptomycinwas success-
ful formanagement ofMRSA bacteremia andwas not adversely affected
by previous vancomycin treatment that included durations of ≥7 days.Funding
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